Please assess the completion status of the following clinical trial:

Trial Title: Study in Plerixafor and Granulocyte-colony Stimulating Factor Patients With Relapse Acute Myeloid Leukemia

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Patients with Acute Myeloid Leukemia in first relapse with first response duration \> 9 months.~* Age between 18 and 65 years.~* Treatment with hydroxyurea or purinethol is allowed if discontinued at least 24 hours before the start of study treatment.~* White blood count less than 30 x 109/L~* Left ventricular ejection fraction more than 50% on echocardiography or multigated acquisition scan or similar radionuclide angiographic scan.~* Total bilirubin less than 1.5 x upper limit of normal= ULN or AST and ALT less than 2.5 x ULN or gammaGT less than 2.5 x ULN.~* Serum creatinine less than 1.5 x ULN and/or creatinine clearance more than 50 ml/mn.~* ECOG performance status less than 2~* Absence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow-up schedule.~* Absence of pregnancy or lactation~* Affiliated to French social security system or similar~* Signed informed consent~Exclusion Criteria:~* AML evolving from MPD and/or secondary AML~* Patients treated with more than 270 mg/m2 of daunorubicin during first line therapy.~* Have any of the following within the last 9 months :~* Unstable supraventricular arrhythmia or patient with a pace-maker~* Any ventricular arrhythmia~* Congestive heart failure~* Myocardial infarction, ischemia, stable coronary disease or angina pectoris~* Syncope with a known cardiovascular etiology~* Known hypersensitivity or contra-indication to drugs used in the protocol = G-CSF, daunorubicin, cytarabine or to excipients.~* Previous treatment with plerixafor.~* Previous hematopoietic stem cell transplantation = Allologous or autologous.~* White blood count more than 30 x 109/L despite treatment with hydroxyurea or purinethol.~* Treatment with chemotherapy or G-CSF within 3 months of screening.~* Uncontrolled active infection.~* Uncontrolled arrythmia~* Grade more than 3 renal dysfunction with serum creatinine more than 1.5 x ULN and/or creatinine clearance less than 50 ml/mn.~* Significant neurologic grade more than 2 or psychiatric disorder, dementia or seizures.~* Clinical symptoms suggesting active central nervous system leukemia.~* Pre-existing disorder predisposing the patient to serious or life-threatening infections = cystic fibrosis, congenital or acquired immunodeficiency, bleeding disorder or cytopenia~* Thrombocytopenia refractory to platelet transfusion~* Anticoagulant therapy~* Severe complications of leukemia such as uncontrolled bleeding, pneumonia with hypoxia or shock or disseminated intravascular coagulation.~* Thrombocytopenia refractory to platelet transfusion.~* Prior total body irradiation more than 10 Gy.~* Known HIV, Hepatitis B or C positivity.~* Participation into a clinical study of an investigational agent within 14 days before study entry.~* Pregnancy or breastfeeding~* Adult patient protected by law~* Concurrent treatment with any other anti-cancer therapy except hydroxyurea

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Plerixafor granulocyte-colony stimulating factor (Type: EXPERIMENTAL): 4 steps of plerixafor doses from 240 to 480 microgram/kg per day concomitant with GCSF and chemotherapy 3 to 6 evaluable patients will be enrolled at each dose level in a modified 3 + 3 design.

Based on this trial design, predict the completion outcome and termination type (if applicable).